The accelerating development during the last 5 y of new compounds for the medical treatment of erectile dysfunction (ED) demands standardized high-quality protocols for evaluation of the therapeutic effect of these treatments. Outcome analyses have to rely on prospective, placebocontrolled trials within predefined populations, where the results are based on good biostatistics, self-administered questionnaires that include partner assessments, quality-of-life measures, and treatment satisfaction. Currently, we have access to different drug application procedures for clinical use in the treatment of ED, and soon we will have new competitive analogues for optional oral treatment. From a wider perspective, we will naturally see second-and third-generation compounds and drugs related to different effector mechanisms. In many subpopulations, ED has a close relation to specific comorbidities, such as cardiovascular diseases and diabetes. Regarding these aspects, the baseline for all clinical trials should be unified and structured not only to evaluate the clinical outcome assessment (subjective and objective) and adverse events as end points, but also to relate the defined therapeutic response to good current clinical practice.
Introduction
We are facing an accelerating development of new pharmaceutical compounds for the medical treatment of erectile dysfunction (ED). In the developing process, new concepts that intervene with important key levels in essential central and peripheral mechanisms of penile erection are being examined. From a total medical perspective of nonsurgical ED therapies, new and existing treatment models have to be considered for the overall ED population; however, from a physician -patient perspective, the therapy programs should be clinically effective in all ED subpopulations. Analogue drugs with the same site of action will continuously appear on the therapeutic stage, creating an expanding pool of treatment options. With regard to these considerations, introduction of new compounds must be related to study results obtained from standardized and unified test protocols, 1 where the clinical outcome assessments are balanced with a defined therapeutic response and good clinical practice. 2 In addition, there is a clinical need for new treatment options and new compounds that offer the patient with ED a better cost-benefit situation.
Rationale of clinical trials
The process of developing a new drug, including the end result of approval for clinical use in ED populations, is long and depends on the outcome of the test situation reported in standardized protocols from different study phases. 2 Phase 1 studies are obligatory and are always performed as the first exposure of the compound to healthy volunteers, where the tolerability and the pharmacokinetics of the drug are controlled in humans.
In the phase 2 studies, the main objective is dose setting. In general, a defined selected population is chosen. Then the efficacy of the drug is tested in a limited number of subjects using a randomized, placebo-controlled, crossover design. It is important that comorbidities are characterized with regard to the ED situation and drug interactions are considered.
The phase 3 studies, which have to be conducted before legal approval, are undertaken as multicenter, prospective, placebo-controlled studies. In general, these studies are double-blind and of a parallel design. A minimum duration of active treatment is set at 8 -12 weeks. Often these phase 3 studies are extended as open-labeled studies for a minimum of 6 months, during which time safety data are collected. It is important that the study population is representative of the ED population as a total in relation to comorbidities. However, this does not exclude special defined ED populations, which need to be focused on when the data are collected and analyzed.
Close to the registration and=or approval stage, phase 4 studies are performed in defined subgroup populations and other agents are compared. Additionally, certain socioeconomic health care aspects may be of specific interest in the evaluation process.
Study populations
Two general principles are important in the structural process of the randomization programs. First, the study population should always be representative of the overall ED population for which the new therapy is planned. Second, the ED status must be specifically characterized and the study population group exactly defined.
Further considerations are the extent and importance of the mechanism of action of the single drug and the typical comorbidities related to ED have for the outcome of the study. All these factors must be clearly distinguished; otherwise, the criteria for inclusion and exclusion may come into conflict with both ethical principles and epidemiological aspects.
Outcome assessments
Every clinical evaluation of drug treatment must measure and compare response variables by pretreatment and post-treatment assessments in relation to already existing treatment modalities. The primary outcome end points should be clarified according to an accepted standardization program before initiation of the actual trial. 2 In addition, strict monitoring of the frequency of adverse events is of absolute importance with regard to drug safety and efficacy.
Objective (physiological) assessments
The RigiScan system has been in clinical use for a long time, especially in recording nocturnal penile tumescence and rigidity during sleep laboratory monitoring. Other physiological procedures to measure penile tumescence and rigidity include volumetric and strain-gauge plethysmography and the specific erectiometers, which mainly register the changes of the penile circumference. However, objective measurements according to such systems have been recently suggested as optional diagnostic tools and are not obligatory in the pretrial screening process. In clinical trials, direct pharmacological testing by intracavernous drug application has not been in routine use and is not recommended as an initial standard in ED populations.
Self-administered assessments
The International Index of Erectile Function (IIEF) is the most frequently used self-administered questionnaire, which is thoroughly validated in most languages with high scores for sensitivity and specificity. 3 Recently, a limited 5-item form (IIEF-5) was introduced as a screening questionnaire recommended for ED subpopulations in clinical practice. 4 Other patient-administered questionnaires are the Brief Male Sexual Function Inventory and the Center for Marital and Sexual Health Questionnaire, both of which have limitations because of inadequate information about treatment responsiveness such as sensitivity and specificity. A fourth questionnaire is the Derogatis Sexual Function Inventory, which is a large, complex measurement of male and female sexual function. The Derogatis Sexual Function Inventory is not recommended for use in clinical trials.
Diary and event logs
Daily use of diaries and specific sexual event logs may be advantageous and is recommended as a complement to self-administered questionnaires, such as the IIEF.
Partner assessments, quality of life and treatment satisfaction
Partner assessments of sexual function are important in the evaluation of the inclusion standards in clinical trials, but until now this has been given lesser priority because of missing standardization of partner ratings. In recent clinical trials, quality of life and treatment satisfaction have been included as outcome end points. An 8-item questionnaire has been structured by Fugl-Meyer et al, 5 and is recommended for further clinical trials. 2 This life satisfaction scale indicated good differentiation between controls and patients with ED and included adequate documentation of the therapeutical response in both groups. The Erectile Dysfunction Inventory of Treatment Satisfaction has been recently used 6 to measure efficacy and satisfaction of patient and partner ratings.
Clinical trial design
A unified approach and common end points regarding analysis of data, reporting of results and ethical issues
All clinical trials have to rely on the World Medical Association's Declaration of Helsinki, which focuses on patient rights and protection in human research. These ethical issues must be the primary concern of involved physicians. Before initiation of a clinical trial, formulated trial protocols should be reviewed and approved by an independent review board. Certain supposed risks for the patients must be balanced with the hypothesized benefits of the trial.
Relying on good data collections from wellstructured protocols, investigators must strictly follow the frames of the protocols in the statistical analysis and presentation of the trial results. In general, the tools of measurement of a therapeutic response and adverse events should mainly rely on reports from self-administered questionnaires.
Information from toxicological analysis and phase 1 studies forms a solid basis for performing phase 2 studies with a crossover design and phase 3 and phase 4 studies. The overall study population must be clearly defined and inclusion and exclusion criteria should respect safety for all patients.
Efficacy, safety end points, and adverse events should be carefully provided and registered. Full information about the project, including supposed risks for the patient, must be objectively transformed to all participating subjects before randomization.
The outcome of a clinical trial should give priority to improvement of the defined treatment in the defined ED population and should be related to the clinical need in the daily practice. The placebo effect is conspicuously high in most trials. This aspect must always be of concern in translating the trial outcome. Theoretically, extended run-in periods of up to 6 months and duration of active treatment, including placebo, of at least 12 months may moderate the placebo effect.
